Ibuprofen Kabi (Ibuprofen)

Ibuprofen works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it reduces pain signalling, lowers the hypothalamic set‑point for temperature, and diminishes the inflammatory response.

The dosing regimen for Ibuprofen Kabi is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other clinical factors. The prescriber selects the appropriate dose, infusion rate and treatment duration according to current medical guidelines.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified health professional.

To order Ibuprofen Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Ibuprofen Kabi offers a familiar NSAID profile with reversible COX inhibition, similar to other IV agents such as ketorolac. Compared with ketorolac, ibuprofen generally has a lower risk of renal toxicity at equivalent analgesic doses, but both share gastrointestinal and bleeding risks. Choice depends on the clinical scenario, patient tolerance and institutional protocols.

Ibuprofen Kabi must be stored refrigerated at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product is inadvertently exposed to temperatures outside this range, it should be discarded.

Ibuprofen Kabi is given by intravenous infusion. The solution is diluted in an appropriate compatible fluid and administered over a short period, typically 15–30 minutes, under continuous monitoring of vital signs and infusion site. Administration is performed by qualified healthcare personnel in a clinical setting.

The most serious risks include severe allergic reactions such as anaphylaxis, acute renal impairment especially in patients with pre‑existing kidney disease or volume depletion, and gastrointestinal bleeding or ulceration. Prompt recognition and management of these events are essential.

Ibuprofen Kabi should be avoided in patients with known hypersensitivity to ibuprofen or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, severe renal insufficiency, uncontrolled hypertension, and in individuals for whom the risk of bleeding outweighs the therapeutic benefit.